FY2017 EPS Estimates for ProMetic Life Sciences Inc. Raised by Analyst (PLI)
ProMetic Life Sciences Inc. (TSE:PLI) – Equities researchers at Hybridan Llp boosted their FY2017 EPS estimates for shares of ProMetic Life Sciences in a research note issued to investors on Thursday. Hybridan Llp analyst D. Nathan now forecasts that the company will post earnings of ($0.16) per share for the year, up from their prior forecast of ($0.18). Hybridan Llp also issued estimates for ProMetic Life Sciences’ FY2018 earnings at ($0.03) EPS.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/21/fy2017-eps-estimates-for-prometic-life-sciences-inc-raised-by-analyst-pli.html.
A number of other research firms have also recently weighed in on PLI. National Bank Financial increased their price objective on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. TD Securities decreased their price objective on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th. Finally, Royal Bank Of Canada decreased their price objective on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a research report on Wednesday, August 16th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of C$3.50.
Shares of ProMetic Life Sciences (PLI) opened at C$1.39 on Monday. ProMetic Life Sciences has a 1 year low of C$1.12 and a 1 year high of C$2.88.
In other ProMetic Life Sciences news, Director Pierre Laurin sold 41,427 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of C$1.45, for a total transaction of C$60,069.15. Also, Director Dwun-Hou Chen sold 32,321 shares of the stock in a transaction on Thursday, August 24th. The shares were sold at an average price of C$1.14, for a total value of C$36,845.94. Over the last three months, insiders have bought 92,900 shares of company stock valued at $116,441 and have sold 388,397 shares valued at $507,577.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.